论文部分内容阅读
目的探讨替吉奥与长春瑞滨联合对晚期乳腺癌的临床效果。方法选择2013年6月至2015年6月收治的晚期乳腺癌患者92例,依据治疗方案分为替吉奥组(单用替吉奥治疗)和联合组(替吉奥联合长春瑞滨治疗),每组46例,比较两组治疗效果。结果替吉奥组疗程(35.67±3.40)d长于联合组(26.19±2.54)d,差异有统计学意义(P<0.05)。替吉奥组总有效率67.4%低于联合组87.0%,差异有统计学意义(P<0.05)。结论替吉奥与长春瑞滨联合对晚期乳腺癌患者临床效果明显。
Objective To investigate the clinical effect of tegaserod combined with vinorelbine on advanced breast cancer. Methods Ninety-two patients with advanced breast cancer who were admitted to our hospital from June 2013 to June 2015 were divided into two groups according to the treatment regimen, namely, the treatment group (group A) and the combination group (group B group) , 46 cases in each group, the treatment effect was compared between the two groups. Results The duration of treatment in the treatment group (35.67 ± 3.40) d was longer than that in the combined group (26.19 ± 2.54) d, the difference was statistically significant (P <0.05). The total effective rate for the group of hippocampus 67.4% was lower than that of the combined group 87.0%, the difference was statistically significant (P <0.05). Conclusion The combination of TEGO and vinorelbine has a significant clinical effect on patients with advanced breast cancer.